blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1896061

EP1896061 - IMMUNOGENIC COMPOSITION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  17.04.2020
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  10.05.2019
FormerGrant of patent is intended
Status updated on  03.01.2019
FormerExamination is in progress
Status updated on  15.03.2017
Most recent event   Tooltip28.05.2021Lapse of the patent in a contracting state
New state(s): CY		published on 30.06.2021  [2021/26]
Applicant(s)For all designated states
GlaxoSmithKline Biologicals S.A.
Rue de l'Institut, 89
1330 Rixensart / BE
[2019/24]
Former [2008/11]For all designated states
GlaxoSmithKline Biologicals S.A.
Rue de l'Institut, 89
1330 Rixensart / BE
Inventor(s)01 / BIEMANS, Ralph L.@GlaxoSmithKline Biologicals s.a.
rue de L'institut 89
B-1330 Rixensart / BE
02 / BOUTRIAU, Dominique@GlaxoSmithKline Biologicals s.a.
rue de L'institut 89
B-1330 Rixensart / BE
03 / CAPIAU, Carine@GlaxoSmithKline Biologicals s.a.
rue de L'institut 89
B-1330 Rixensart / BE
04 / DENOEL, Philippe@GlaxoSmithKline Biologicals s.a.
rue de L'institut 89
B-1330 Rixensart / BE
05 / DUVIVIER, Pierre@GlaxoSmithKline Biologicals s.a.
rue de L'institut 89
B-1330 Rixensart / BE
06 / POOLMAN, Jan@GlaxoSmithKline Biologicals s.a.
rue de L'institut 89
B-1330 Rixensart / BE
 [2019/04]
Former [2008/11]01 / BIEMANS, Ralph L. GlaxoSmithKline Biologicals s.a.
rue de L'institut 89
B-1330 Rixensart / BE
02 / BOUTRIAU, Dominique GlaxoSmithKline Biologicals
rue de L'institut 89
B-1330 Rixensart / BE
03 / CAPIAU, Carine GlaxoSmithKline Biologicals s.a.
rue de L'institut 89
B-1330 Rixensart / BE
04 / DENOEL, Philippe GlaxoSmithKline Biologicals s.a.
rue de L'institut 89
B-1330 Rixensart / BE
05 / DUVIVIER, Pierre GlaxoSmithKline Biologicals s.a.
rue de L'institut 89
B-1330 Rixensart / BE
06 / POOLMAN, Jan GlaxoSmithKline Biologicals s.a.
rue de L'institut 89
B-1330 Rixensart / BE
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2019/24]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2008/11]Johnston, Caroline Louise
GlaxoSmithKline Corporate Intellectual Property (CN925.1) 980 Great West Road Brentford
Middlesex TW8 9GS / GB
Application number, filing date06754582.223.06.2006
[2008/11]
WO2006EP06188
Priority number, dateGB2005001307127.06.2005         Original published format: GB 0513071
GB2005001306927.06.2005         Original published format: GB 0513069
GB2005001555628.07.2005         Original published format: GB 0515556
GB2005002420428.11.2005         Original published format: GB 0524204
GB2005002604021.12.2005         Original published format: GB 0526040
GB2005002604121.12.2005         Original published format: GB 0526041
[2008/11]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2007000314
Date:04.01.2007
Language:EN
[2007/01]
Type: A2 Application without search report 
No.:EP1896061
Date:12.03.2008
Language:EN
The application published by WIPO in one of the EPO official languages on 04.01.2007 takes the place of the publication of the European patent application.
[2008/11]
Type: B1 Patent specification 
No.:EP1896061
Date:12.06.2019
Language:EN
[2019/24]
Search report(s)International search report - published on:EP31.05.2007
ClassificationIPC:A61K39/00, A61K39/385, A61K39/145, C07H3/00, C12N7/00, A61K39/095, A61K39/102
[2018/50]
CPC:
A61K39/385 (EP,NO,US); A61K39/0017 (EP,NO,US); A61K39/095 (EP,KR,NO,US);
A61K39/0018 (EP,NO,US); A61K39/05 (NO,US); A61K39/08 (NO,US);
A61K39/092 (NO,US); A61K39/099 (NO,US); A61K39/102 (EP,KR,NO,US);
A61K39/116 (KR,NO,US); A61K39/12 (NO,US); A61K39/145 (NO,US);
A61K39/292 (NO,US); A61P11/04 (EP,NO); A61P11/14 (EP);
A61P31/00 (EP,NO); A61P31/04 (EP,NO); A61P31/12 (EP,NO);
A61P31/20 (EP); A61P37/00 (EP,NO); A61P37/04 (EP,NO);
A61P43/00 (EP); C07H3/00 (EP,US); C12N7/00 (US);
A61K2039/545 (EP,US); A61K2039/55 (US); A61K2039/575 (US);
A61K2039/6037 (EP,NO,US); A61K2039/62 (EP,NO,US); A61K2039/627 (EP,NO,US);
A61K2039/70 (EP,NO,US); C12N2730/10134 (EP,NO,US); C12N2760/16234 (NO,US);
C12N2760/16271 (US); C12N2770/32634 (EP,NO,US); Y02A50/30 (EP,NO,US) (-)
Former IPC [2008/11]A61K39/095, A61K39/102, A61K39/116, A61P31/04
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2019/24]
Former [2008/11]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesHR18.12.2007
TitleGerman:IMMUNOGENE ZUSAMMENSETZUNG[2008/11]
English:IMMUNOGENIC COMPOSITION[2008/11]
French:COMPOSITION IMMUNOGENE[2008/11]
Entry into regional phase18.12.2007National basic fee paid 
18.12.2007Designation fee(s) paid 
18.12.2007Examination fee paid 
Examination procedure11.06.2007Request for preliminary examination filed
International Preliminary Examining Authority: EP
18.12.2007Amendment by applicant (claims and/or description)
18.12.2007Examination requested  [2008/11]
28.05.2008Despatch of a communication from the examining division (Time limit: M04)
24.07.2008Reply to a communication from the examining division
30.03.2009Observations by third parties
26.11.2010Despatch of a communication from the examining division (Time limit: M04)
04.04.2011Reply to a communication from the examining division
12.12.2012Despatch of a communication from the examining division (Time limit: M06)
21.06.2013Reply to a communication from the examining division
12.09.2014Despatch of a communication from the examining division (Time limit: M06)
17.03.2015Reply to a communication from the examining division
13.11.2015Despatch of a communication from the examining division (Time limit: M06)
23.05.2016Reply to a communication from the examining division
06.03.2017Despatch of a communication from the examining division (Time limit: M06)
15.09.2017Reply to a communication from the examining division
07.11.2018Date of oral proceedings
27.11.2018Minutes of oral proceedings despatched
04.01.2019Communication of intention to grant the patent
02.05.2019Fee for grant paid
02.05.2019Fee for publishing/printing paid
02.05.2019Receipt of the translation of the claim(s)
Divisional application(s)EP10177832.2  / EP2283857
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.05.2008
Opposition(s)13.03.2020No opposition filed within time limit [2020/21]
Fees paidRenewal fee
18.03.2008Renewal fee patent year 03
05.06.2009Renewal fee patent year 04
31.03.2010Renewal fee patent year 05
07.06.2011Renewal fee patent year 06
31.03.2012Renewal fee patent year 07
31.03.2013Renewal fee patent year 08
31.03.2014Renewal fee patent year 09
05.06.2015Renewal fee patent year 10
31.03.2016Renewal fee patent year 11
07.06.2017Renewal fee patent year 12
07.06.2018Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY12.06.2019
EE12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
IS12.11.2019
[2021/26]
Former [2020/36]EE12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
IS12.11.2019
Former [2020/24]EE12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
IS24.02.2020
Former [2020/17]EE12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
IS12.10.2019
Former [2020/12]EE12.06.2019
LT12.06.2019
LV12.06.2019
IS12.10.2019
Former [2019/52]LT12.06.2019
LV12.06.2019
Former [2019/47]LT12.06.2019
Cited inInternational search[DX] WO2004103400  (AVENTIS PASTEUR INC et al.) [DX] 1-68 * page 6, line 11 - page 7, line 21 * * page 9, line 4 - page 10, line 2 * * example -; claim - *
 [A] WO03080678  (CHIRON SRL et al.) [A] 1-68 * page 1, line 4 - line 26 * * page 11, line 12 - line 29 * * page 12, line 15 - line 20 * * page 14, line 17 - line 27 * * page 14, line 32 - page 15, line 13 * * page 26, line 6 - line 9 * * example -; claim - *
 [A] WO03007985  (CHIRON SPA et al.) [A] 1-68 * page 1, line 29 - line 32 * * page 4, line 12 - page 6, line 14 * * page 8, line 1 - line 32 * * page 15, line 10 - line 18 * * example -; claim - *
ExaminationWO2004110480
 US2004096461
otherWO2008011201
   CONSTANTINO P. ET AL: "DEVELOPMENT AND PHASE 1 CLINICAL TESTING OF A CONJUGATE VACCINE AGAINST MENINGOCOCCUS A AND C", VACCINE, vol. 10, no. 10, 1 January 1992 (1992-01-01), pages 691 - 698, XP001000401

DOI:   http://dx.doi.org/10.1016/0264-410X(92)90091-W
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.